At CTS, we understand the impact converting to the Ortho viral marker platform has on your operations. As we get closer to our implementation date of January 11, 2021 we are committed to providing you information as it becomes available.
Package inserts for the new assays are now available. You can review them on the Communications page by clicking this link: Communications,
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...